Stock Taper 
KEY STATISTICS
COMPANY
LEADERSHIP
COMPENSATION 2026
ABOUT
PRICE TARGET
UPCOMING EARNINGS
SPLIT RECORD
| DATE | TYPE | RATIO |
|---|---|---|
| 2019-03-18 | Reverse | 1:20 |
ETFS HOLDING THIS STOCK
INSTITUTIONAL OWNERSHIP
PRICE
$1.20 ▲ UP 60.32% (+$0.45)About PDS Biotechnology Corporation
https://www.pdsbiotech.com ↗PDS Biotechnology, a clinical-stage biopharma founded in 2005, develops multifunctional cancer immunotherapies and vaccines, with lead candidates in Phase II trials and collaborations with NIH, Merck, HHS, and MSD.
INDUSTRY
A PRODUCT PDS BIOTECHNOLOGY CORPORATION IS KNOWN FOR
An investigational T-cell activating immunotherapy designed to treat various HPV-positive cancers. As the company's lead candidate in a pivotal Phase 3 clinical trial, it represents PDS Biotechnology's most prominent and actively developed product.
PDS Biotechnology in 2025
PDS Biotech Gains FDA Alignment for Accelerated Approval Pathway for its Lead Cancer Immunotherapy, PDS0101
In December 2025, PDS Biotechnology announced it had scheduled a Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss a potential accelerated approval pathway for its lead investigational immunotherapy, PDS0101, for the treatment of HPV16-positive head and neck cancer. Following this meeting, the company announced in January 2026 that it had gained alignment with the FDA on using Progression-Free Survival (PFS) as a primary endpoint in its Phase 3 VERSATILE-003 trial, a key step that could shorten the trial duration and lead to an earlier regulatory submission for accelerated approval.
PDS Biotechnology Pursues Accelerated FDA Approval Pathway for Lead Cancer Drug PDS0101
In a significant strategic move, PDS Biotechnology actively engaged with the U.S. Food and Drug Administration (FDA) to amend the clinical trial design for its lead product candidate, PDS0101. The company is seeking to use Progression-Free Survival (PFS) as a primary endpoint to potentially shorten the timeline for regulatory approval for the treatment of HPV16-positive head and neck cancer, a move that could bring its key asset to market sooner.
RATINGS SNAPSHOT
Overall rating: C+
MOST RECENT ANALYST GRADES
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 OKUR | $2.65 | COMPARE |
 XLO | $9.26 | COMPARE |
 INMB | $1.94 | COMPARE |
 ANVS | $1.17 | COMPARE |
 TPST | $0.79 | COMPARE |
 RVPH | $0.51 | COMPARE |